Chemical Structure (Inotersen 01)
Tegsedi
Product Images NDC 72126-007
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Tegsedi (NDC 72126-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Akcea Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Change From Baseline In Mnis+7 (Inotersen 02)
Figure 2: Histogram Of Mnis+7 Change From Baseline At Week 66 (Inotersen 03)
Figure 3: Change From Baseline In Norfolk Qol-dn Score (Inotersen 04)
Figure 4: Histogram Of Norfolk Qol-dn Change From Baseline At Week 66 (Inotersen 05)
This seems to be a chart or table showing the percentage of patients who had a change in their quality of life related to neuropathic pain in Norfolk. The table presents different categories of change, including "better" and "worse", and the number of patients in each category. However, without additional context it is difficult to understand the significance of these findings.*
Instructions For Use (Figure 1)
This is a description of a medical device that likely involves the use of a plunger, finger grip, and needle. There is an expiration date provided on the body of the device. The text also suggests that the device has a safety feature that automatically retracts the needle after use. However, part of the text is not available due to errors.*
Instructions For Use (Figure 2)
Instructions For Use (Figure 3)
Instructions For Use (Figure 4)
Instructions For Use (Figure 5)
Instructions For Use (Figure 6)
Instructions For Use (Figure 7)
Instructions For Use (Figure 8)
Instructions For Use (Figure 9)
Instructions For Use (Figure 10)
This text is a set of instructions that guide someone on how to use a plunger. It advises them to hold the plunger fully down and wait for five seconds.*
Instructions For Use (Figure 11)
Instructions For Use (Figure 12)
Syringe Label (Inotersen 18)
Tegsedi is a medication available in injection form. It contains 284 milligrams per 1.5 milliliters or equivalent to 300 milligrams of inotersen sodium. It is intended for subcutaneous use and is manufactured by Akcea Therapeutics, Inc. The product has an expiry date indicated as MMM YYYY and a lot number identified as (01)00372126007028.*
1-count Tray Label (Inotersen 19)
This is a product packaging for Tegsedi, an injection used for subcutaneous use. It contains 284 mg of inotersen, equivalent to 300 mg of inotersen sodium in a 1.5 mL of sterile solution. The product should not be frozen and must be protected from light. It is distributed by Sobi, Inc. located in Waltham, MA 02451.*
4-count Carton Label (Inotersen 20)
Tegsedi® L is a sterile solution for subcutaneous injection containing 284 mg of inotersen per 1.5 mL prefilled syringe. The solution should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light. The solution can be stored at room temperature up to 30°C (86°F) for up to six weeks after dispensing. The package contains four prefilled syringes. The inactive ingredients in the solution include sodium hydroxide, hydrochloric acid, and water for injection. The prescribing information and instructions for use should be followed for dosage and administration.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
